212 related articles for article (PubMed ID: 36251231)
1. Clinical characteristics of steroid-responsive but dependent chronic graft-versus-host disease: a multicenter retrospective analysis.
Oyama T; Matsuda K; Honda A; Maki H; Masamoto Y; Murakami D; Toya T; Sakurai M; Kataoka K; Doki N; Kurokawa M
Int J Hematol; 2023 Feb; 117(2):260-268. PubMed ID: 36251231
[TBL] [Abstract][Full Text] [Related]
2. Steroid-Refractory Chronic Graft-Versus-Host Disease: Treatment Options and Nursing Care.
Cazeau N; Rodriguez S
Clin J Oncol Nurs; 2023 May; 27(3):259-265. PubMed ID: 37267484
[TBL] [Abstract][Full Text] [Related]
3. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.
Belina ME; Driscoll TA; Blanchard SK; Cardones AR
Pediatr Dermatol; 2022 May; 39(3):432-433. PubMed ID: 35234308
[TBL] [Abstract][Full Text] [Related]
5. A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy In Heavily Pretreated Chronic GVHD Patients With Steroid Failure.
White J; Elemary M; Linn SM; Novitzky-Basso I; Culos S; Tan SK; Kelly K; Deotare U; Xenocostas A; Hamad N; Law A; Kumar R; Kim DDH
Transplant Cell Ther; 2023 Feb; 29(2):120.e1-120.e9. PubMed ID: 36460202
[TBL] [Abstract][Full Text] [Related]
6. Treatment-Sensitive and Treatment-Dependent Chronic Graft-versus-Host Disease Yield Superior Failure-Free and Overall Survival Compared to Treatment-Resistant Chronic Graft-versus-Host Disease.
El Jurdi N; Herzog S; Shanley R; Holtan SG; MacMillan ML; Weisdorf DJ
Transplant Cell Ther; 2024 Jun; 30(6):616-625. PubMed ID: 38479549
[TBL] [Abstract][Full Text] [Related]
7. Isolated massive pleural effusion as a manifestation of chronic graft versus host disease successfully treated with corticosteroid.
Masuda Y; Yamazaki S; Honda A; Masamoto Y; Kurokawa M
Ann Hematol; 2024 Apr; 103(4):1403-1407. PubMed ID: 38285080
[TBL] [Abstract][Full Text] [Related]
8. Spectacular and Prompt Response to Extracorporeal Photopheresis for Refractory Cutaneous Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.
Spałek A; Grygoruk-Wiśniowska I; Gruenpeter K; Panz-Klapuch M; Helbig G
Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556924
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study.
Liu J; Fan Z; Xu N; Ye J; Chen Y; Shao R; Sun Y; Wu Q; Liu Q; Jin H
Ann Hematol; 2023 Oct; 102(10):2865-2877. PubMed ID: 37474631
[TBL] [Abstract][Full Text] [Related]
10. Updates in chronic graft-versus-host disease management.
Malard F; Mohty M
Am J Hematol; 2023 Oct; 98(10):1637-1644. PubMed ID: 37483142
[TBL] [Abstract][Full Text] [Related]
11. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.
Lin C; DiCioccio RA; Haykal T; McManigle WC; Li Z; Anand SM; Poe JC; Bracken SJ; Jia W; Alyea EP; Cardones AR; Choi T; Gasparetto C; Grunwald MR; Hennig T; Kang Y; Long GD; Lopez R; Martin M; Minor KK; Quinones VLP; Sung AD; Wiggins K; Chao NJ; Horwitz ME; Rizzieri DA; Sarantopoulos S
Transplant Cell Ther; 2023 Mar; 29(3):179.e1-179.e10. PubMed ID: 36577483
[TBL] [Abstract][Full Text] [Related]
12. Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients.
Lueck C; Tzalavras A; Wohlfarth P; Meedt E; Kiehl M; Turki AT; Hoeper MM; Eder M; Cserna J; Buchtele N; Wolff D; Schellongowski P; Beutel G; Liebregts T
Bone Marrow Transplant; 2023 Mar; 58(3):303-310. PubMed ID: 36496524
[TBL] [Abstract][Full Text] [Related]
13. [Recent advances in prevention and treatment of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
Toubai T; Hosokawa Y
Rinsho Ketsueki; 2024; 65(5):401-411. PubMed ID: 38825520
[TBL] [Abstract][Full Text] [Related]
14. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
Front Immunol; 2021; 12():673636. PubMed ID: 34276662
[TBL] [Abstract][Full Text] [Related]
15. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
[TBL] [Abstract][Full Text] [Related]
16. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
[TBL] [Abstract][Full Text] [Related]
17. Population-based real-world registry study to evaluate clinical outcomes of chronic graft-versus-host disease.
Novitzky-Basso I; Schain F; Batyrbekova N; Webb T; Remberger M; Keating A; Mattsson J
PLoS One; 2023; 18(3):e0282753. PubMed ID: 36893113
[TBL] [Abstract][Full Text] [Related]
18. Impact of Center Volume on Chronic Graft Versus Host Disease in Patients With Allogeneic Stem Cell Transplantation.
Shimomura Y; Kitamura T; Murata M; Matsuo K; Ito Y; Ichinohe T; Hashii Y; Goto H; Kato K; Ishimaru F; Sato A; Onizuka M; Yanagisawa A; Ohbiki M; Tabuchi K; Atsuta Y; Fukuda T; Kanda J; Terakura S
Transplant Cell Ther; 2024 Mar; 30(3):326.e1-326.e14. PubMed ID: 38218451
[TBL] [Abstract][Full Text] [Related]
19. Healthcare resource utilization and costs among patients with steroid-resistant chronic graft-versus-host disease in the United States: a retrospective claims database analysis.
Yu J; Lal LS; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
Curr Med Res Opin; 2021 May; 37(5):755-759. PubMed ID: 33615925
[TBL] [Abstract][Full Text] [Related]
20. Low-dose rituximab in steroid-refractory chronic graft-versus-host disease.
Colunga-Pedraza PR; Barbosa-Castillo LM; Coronado-Alejandro EU; Vaquera-Alfaro HA; López-Reyna IG; Colunga-Pedraza JE; Gómez-Almaguer D
Transpl Immunol; 2023 Dec; 81():101959. PubMed ID: 37972876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
